Abstract:Aptamers are short single-strand oligonucleotides that can form secondary and tertiary structures, fitting targets with high affinity and specificity. They are so-called "chemical antibodies" and can target specific biomarkers in both diagnostic and therapeutic applications. Systematic evolution of ligands by exponential enrichment (SELEX) is usually used for the enrichment and selection of aptamers, and the targets could be metal ions, small molecules, nucleotides, proteins, cells, or even tissues or organs. Due to the high specificity and distinctive binding affinity of aptamers, aptamer-drug conjugates (ApDCs) have demonstrated their potential role in drug delivery for cancer-targeting therapies. Compared with antibodies which are produced by a cell-based bioreactor, aptamers are chemically synthesized molecules that can be easily conjugated to drugs and modified; however, the conventional ApDCs conjugate the aptamer with an active drug using a linker which may add more concerns to the stability of the ApDC, the drug-releasing efficiency, and the drug-loading capacity. The function of aptamer in conventional ApDC is just as a targeting moiety which could not fully perform the advantages of aptamers. To address these drawbacks, scientists have started using active nucleotide analogs as the cargoes of ApDCs, such as clofarabine, ara-guanosine, gemcitabine, and floxuridine, to replace all or part of the natural nucleotides in aptamer sequences. In turn, these new types of ApDCs, aptamer nucleotide analog drug conjugates, show the strength for targeting efficacy but avoid the complex drug linker designation and improve the synthetic efficiency. More importantly, these classic nucleotide analog drugs have been used for many years, and aptamer nucleotide analog drug conjugates would not increase any unknown druggability risk but improve the target tumor accumulation. In this review, we mainly summarized aptamer-conjugated nucleotide analog drugs in cancer-targeting therapies.

Construction of Bispecific Aptamer–Drug Conjugate by a Hybrid Chemical and Biological Approach

Polymeric Engineering of Aptamer-Drug Conjugates for Targeted Cancer Therapy.

Automated Modular Synthesis of Aptamer–Drug Conjugates for Targeted Drug Delivery

Molecular Engineering‐Based Aptamer–Drug Conjugates with Accurate Tunability of Drug Ratios for Drug Combination Targeted Cancer Therapy

A Basic Insight into Aptamer-Drug Conjugates (Apdcs).

Recent Progress of Aptamer‒drug Conjugates in Cancer Therapy

Programmable Repurposing of Existing Drugs as Pharmaceutical Elements for the Construction of Aptamer–Drug Conjugates

Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers

Advances in the Development of Aptamer Drug Conjugates for Targeted Drug Delivery.

Stimuli-Responsive Aptamer-Drug Conjugates for Targeted Drug Delivery and Controlled Drug Release

Advances In The Development Of Aptamer Drug Conjugates For Targeted Drug Delivery

Endocytic Pathways and Intracellular Transport of Aptamer-Drug Conjugates in Live Cells Monitored by Single-Particle Tracking

Artificial Base-Directed In Vivo Formulation of Aptamer–Drug Conjugates with Albumin for Long Circulation and Targeted Delivery

Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells.

Enzymatic interlocking aptamer-micelles for enhanced cellular internalization and nucleus-targeted cancer phototherapy

Aptamers Entirely Built from Therapeutic Nucleoside Analogues for Targeted Cancer Therapy.

Enhancing Anti‐pd‐1 Immunotherapy by Nanomicelles Self‐Assembled from Multivalent Aptamer Drug Conjugates

Modularly Engineered Solid-Phase Synthesis Of Aptamer-Functionalized Small Molecule Drugs For Targeted Cancer Therapy

Building a Multifunctional Aptamer-Based DNA Nanoassembly for Targeted Cancer Therapy.

Synthesis of site‐specific Fab‐drug conjugates using ADP‐ribosyl cyclases

Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy